Eyepoint Pharmaceuticals (EYPT) financial statements
Eyepoint Pharmaceuticals reported revenue of $31M in fiscal 2025, up 17.2% a year over 9 years.
Net income was -$232M and the operating margin -776.0%, against -246.4% in 2017.
Free cash flow was -$243M.
The diluted share count rose 107% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Eyepoint Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $3M | $5M | $20M | $34M | $37M | $41M | $46M | $43M | $31M |
| Cost of revenue | — | — | — | — | — | — | — | $5M | $4M | $2M |
| Gross profit | — | — | — | — | — | — | — | $41M | $40M | $29M |
| Research and development | $15M | $16M | $19M | $15M | $17M | $28M | $50M | $65M | $133M | $221M |
| Selling, general and admin | $11M | $13M | $25M | $48M | $46M | $53M | $60M | $52M | $52M | $52M |
| Operating income | -$19M | -$26M | -$39M | -$48M | -$37M | -$55M | -$100M | -$75M | -$146M | -$243M |
| Interest expense | $0 | $720,000 | $2M | $6M | $7M | $5M | $3M | $1M | $14,000 | $33,000 |
| Pre-tax income | -$18M | -$53M | — | -$57M | -$45M | -$58M | -$102M | -$71M | -$131M | -$232M |
| Income tax | $0 | $0 | — | $0 | $0 | $0 | $0 | $83,000 | $90,000 | $279,000 |
| Net income | -$18M | -$53M | -$86M | -$57M | -$45M | -$58M | -$102M | -$71M | -$131M | -$232M |
| EPS (diluted) | -$0.52 | -$1.15 | -$1.27 | -$5.44 | -$3.54 | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
| Diluted shares | 35M | 46M | 68M | 10M | 13M | 29M | 37M | 39M | 56M | 73M |
| Gross margin | — | — | — | — | — | — | — | 89.9% | 91.4% | 93.4% |
| Operating margin | -246.4% | -887.3% | -853.6% | -235.0% | -108.3% | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Net margin | -245.2% | -1795.7% | -1884.2% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
Balance sheet
Fiscal years, from Eyepoint Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $17M | $39M | $45M | $22M | $45M | $212M | $145M | $331M | $371M | $306M |
| Inventory | $0 | $0 | $279,000 | $2M | $5M | $4M | $3M | $4M | $2M | $2M |
| Total current assets | $18M | $40M | $48M | $42M | $63M | $238M | $173M | $345M | $383M | $329M |
| Property, plant and equipment | $313,000 | $253,000 | $288,000 | $357,000 | $630,000 | $476,000 | $1M | $5M | $8M | $9M |
| Total assets | $19M | $72M | $78M | $73M | $92M | $263M | $180M | $355M | $418M | $364M |
| Total current liabilities | $5M | $22M | $21M | $12M | $15M | $24M | $35M | $63M | $49M | $37M |
| Long-term debt | $0 | $17M | $18M | $47M | $38M | $37M | $29M | — | — | — |
| Total liabilities | $5M | $60M | $41M | $65M | $73M | $79M | $84M | $89M | $82M | $58M |
| Shareholders' equity | $13M | $12M | $38M | $8M | $19M | $184M | $96M | $266M | $337M | $306M |
| Net debt | -$17M | -$21M | -$28M | $25M | -$7M | -$142M | -$66M | -$281M | -$100M | -$102M |
Cash flow
Fiscal years, from Eyepoint Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20M | -$22M | — | -$57M | -$14M | -$50M | -$65M | $2M | -$126M | -$240M |
| Capital spending | $147,000 | $108,000 | — | $213,000 | $362,000 | $156,000 | $2M | $3M | $4M | $3M |
| Free cash flow | -$21M | -$22M | — | -$57M | -$15M | -$50M | -$67M | -$2M | -$130M | -$243M |
| Stock-based compensation | $2M | $3M | — | $5M | $6M | $7M | $14M | $12M | $37M | $28M |
| Net borrowing | $0 | $20M | — | $30M | -$14M | $0 | -$8M | -$30M | $0 | — |
| Free cash flow margin | -273.7% | -743.5% | — | -279.5% | -43.0% | -136.0% | -162.2% | -3.5% | -301.1% | -775.8% |
Questions
What was Eyepoint Pharmaceuticals's revenue in 2025?
$31M in fiscal 2025, from its 10-K filing.
How much free cash flow does Eyepoint Pharmaceuticals generate?
-$243M in fiscal 2025 (operating cash flow minus capital spending).
From Eyepoint Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.